

Lavipharm announces launch in Greece of the first locally produced cannabis-based prescription medicine

Peania, 23 February 2024 – Lavipharm, the leading pharmaceutical company with over a century of history, announced the launch of the first locally produced cannabis-based prescription medicine.

The pharmaceutical product is launched on the Greek market as a result of Lavipharm's strategic partnership with Tikun Olam and is produced at the latter's plant in Corinth, following strict international quality and safety standards.

At the successful event, which was held on Thursday, 22 February 2024, at the auditorium of the Basil & Elise Goulandris Foundation, medicinal cannabis was lauded for its ability to treat serious symptoms of chronic conditions that afflict the quality of life of countless individuals. **Minister of Health Adonis Georgiadis** greeted the event.

Telemaque Lavidas, Executive Board Member, opening the event, noted that *"this historic occasion signifies a leap forward in our approach to healthcare,"* appreciating all the scientists, regulators, policymakers, and patient groups for their tireless efforts that have laid the foundation for a more inclusive healthcare system. A reality made also possible by the pioneering company Tikun Olam and its vision to industrially produce medical cannabis products and are now available to patients in Greece by Lavipharm. In closing, Mr. Lavidas stressed that *"tonight we celebrate for all the patients whose lives will be forever changed by this moment. For them, the prescription of medical cannabis is not just a treatment – it is a lifeline, offering hope, relief and a better tomorrow."*

The event's speakers – representatives of the academic and scientific communities and authorities – highlighted the potential of medicinal cannabis to now become another powerful option in healthcare professionals' therapeutic choices, improving patients' quality of life.

Lavipharm, listed on the Athens Stock Exchange since 1995 (LAVI), is a pharmaceutical company with a rich legacy in advancing patient care through pioneering healthcare solutions. Since 1911, Lavipharm has a long and successful history of commercial operations in the prescription medicines and self-care products markets in Greece. Globally recognised for its expertise in the development and production of transdermal drug delivery systems (TDDS), Lavipharm has a robust presence in major markets around the world. For over 110 years, Lavipharm has been enabling people to live healthier and longer lives. <https://lavipharm.com/>

###

For further information:
Katerina Fragioudakis
Corporate Communications
Lavipharm
tel. 210 6691 106
communications@lavipharm.com